Patient engagement in first cycle comprehensive chemotherapy consultation pharmacist services and impact on patient activation.
J Oncol Pharm Pract
; 25(4): 896-902, 2019 Jun.
Article
en En
| MEDLINE
| ID: mdl-30808278
ABSTRACT
BACKGROUND:
Healthcare systems and policy makers worldwide are demonstrating interest in shared decision making, which requires patient activation. Patient activation can be measured using a validated tool called the patient activation measure-10. First cycle comprehensive chemotherapy consultation services (3CS) is provided by an oncology pharmacy team member during a patient encounter at the beginning of the patient's treatment for cancer.METHODS:
This was a single center, prospective, non-randomized, observational clinical study in patients with cancer who required a new chemotherapy plan. A baseline patient activation measure-10 survey was administered and a pharmacy team member met with the patient to complete the first cycle 3CS encounter. Within two business days of that encounter, a second patient activation measure-10 survey was administered, and thus, patients served as their own control.RESULTS:
Forty-nine patients who met the inclusion criteria were enrolled, of which 36 completed the study. Mean patient activation measure-10 scores measured at baseline and two business days after the 3CS encounter were significantly different (68.5 ± SD 14.7 vs. 75.0 ± SD 14.3, p = 0.001). This difference persisted when evaluated by gender (female 70.0 ± SD 14.8 vs. 81.6 ± SD 10.5, p = 0.001; male 66.1 ± SD 14.8 vs. 70.8 ± SD 14.7, p = 0.022).CONCLUSION:
This study demonstrates that cancer patients had significantly increased patient activation scores after engagement in a 3CS encounter provided by an oncology pharmacy team. Further studies are needed to verify these data in a larger population, different healthcare settings, and to evaluate for patients who have solid tumor malignancies.Palabras clave
Texto completo:
1
Bases de datos:
MEDLINE
Asunto principal:
Farmacéuticos
/
Servicios Farmacéuticos
/
Derivación y Consulta
/
Neoplasias
Tipo de estudio:
Clinical_trials
/
Observational_studies
/
Prognostic_studies
Límite:
Adult
/
Aged
/
Female
/
Humans
/
Male
/
Middle aged
Idioma:
En
Revista:
J Oncol Pharm Pract
Asunto de la revista:
FARMACIA
Año:
2019
Tipo del documento:
Article
País de afiliación:
Estados Unidos